SEC approves fund that levers up MicroStrategy, which bets on bitcoin
By Steve Goldstein
Analyst says the fund may be the most volatile ETF available in the U.S.
Investors will now have the opportunity to buy a fund leveraged to a company that is leveraged to an asset that often is bought on leverage.
Got that? The Securities and Exchange Commission has approved the Defiance Daily Target 1.75X Long MSTR ET , which seeks daily leveraged investment returns of 1.75 times the daily percentage change in MicroStrategy.
MicroStrategy (MSTR), under the direction of founder Michael Saylor, is an IT firm that has been issuing convertible debt to buy bitcoin (BTCUSD).
The fund carries a hefty management fee of 1.29%, but buyers of this product would be seeking super-sized quick returns.
MicroStrategy's annualized historical volatility rate for the five-year period ended March 31, 2024 was 84.19% - and this fund is leveraged to MicroStrategy.
Eric Balchunas, Bloomberg Intelligence's ETF analyst, said in a social-media post that the fund will be the most volatile ETF available in the U.S. market.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-15-24 0803ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks